PL1660037T3 - Zawiesina arypiprazolu do wstrzykiwania - Google Patents

Zawiesina arypiprazolu do wstrzykiwania

Info

Publication number: PL1660037T3
Authority: PL; Poland
Prior art keywords: extended release; aripiprazole; injectable suspension; aripiprazole injectable; injection
Prior art date: 2003-08-06

Application number

PL04779411T

Other languages

English (en)

Inventor

Josiah Brown

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-06

Filing date

2004-07-29

Publication date

2012-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34116189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1660037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-07-29 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2012-03-30 Publication of PL1660037T3 publication Critical patent/PL1660037T3/pl

Links

CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 2
229960004372 aripiprazole Drugs 0.000 title abstract 2
229940102213 injectable suspension Drugs 0.000 title 1
238000013265 extended release Methods 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
238000002347 injection Methods 0.000 abstract 2
239000007924 injection Substances 0.000 abstract 2
239000004005 microsphere Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Dispersion Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL04779411T 2003-08-06 2004-07-29 Zawiesina arypiprazolu do wstrzykiwania PL1660037T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/635,221 US20050032811A1 (en)	2003-08-06	2003-08-06	Methods for administering aripiprazole
EP04779411A EP1660037B1 (en)	2003-08-06	2004-07-29	Aripiprazole injectable suspension
PCT/US2004/024345 WO2005016262A2 (en)	2003-08-06	2004-07-29	Methods for administering aripiprazole

Publications (1)

Publication Number	Publication Date
PL1660037T3 true PL1660037T3 (pl)	2012-03-30

Family

ID=34116189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04779411T PL1660037T3 (pl)	2003-08-06	2004-07-29	Zawiesina arypiprazolu do wstrzykiwania

Country Status (21)

Country	Link
US (9)	US20050032811A1 (pl)
EP (2)	EP2340810A1 (pl)
JP (3)	JP5300194B2 (pl)
CN (2)	CN102133171A (pl)
AT (1)	ATE522200T1 (pl)
AU (1)	AU2004264886C1 (pl)
CA (1)	CA2534997C (pl)
CY (1)	CY1111874T1 (pl)
DK (1)	DK1660037T3 (pl)
ES (1)	ES2369893T3 (pl)
HR (1)	HRP20110646T1 (pl)
IL (1)	IL173441A (pl)
MX (1)	MXPA06001350A (pl)
NO (1)	NO339816B1 (pl)
NZ (1)	NZ545037A (pl)
PL (1)	PL1660037T3 (pl)
PT (1)	PT1660037E (pl)
SE (1)	SE1660037T5 (pl)
SI (1)	SI1660037T1 (pl)
WO (1)	WO2005016262A2 (pl)
ZA (1)	ZA200601385B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770478B2 (en) *	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells
US20050032811A1 (en) *	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
ATE411797T2 (de) *	2003-10-23	2008-11-15	Otsuka Pharma Co Ltd	Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
TWI371274B (en) *	2003-10-23	2012-09-01	Bristol Myers Squibb Co	Process for making sterile aripiprazole of desired mean particle size
CA2622758A1 (en) *	2005-09-15	2007-03-29	Elan Pharma International, Limited	Nanoparticulate aripiprazole formulations
WO2007061896A1 (en) *	2005-11-17	2007-05-31	Zogenix, Inc.	Delivery of viscous formulations by needle-free injection
EP1880714A1 (en)	2006-07-20	2008-01-23	Helm AG	Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en)	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
MX2009014115A (es) *	2007-06-25	2010-04-21	Otsuka Pharma Co Ltd	Microesferas que tienen estructura de nucleo/corteza.
MY152789A (en) *	2007-07-31	2014-11-28	Otsuka Pharma Co Ltd	Methods for producing aripiprazole suspension and freeze-dried formulation
CA2937222C (en) *	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
LT2445502T (lt)	2009-06-25	2017-09-25	Alkermes Pharma Ireland Limited	Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
AU2011270701B2 (en)	2010-06-24	2015-05-14	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP5893616B2 (ja)	2010-10-18	2016-03-23	大日本住友製薬株式会社	注射用徐放性製剤
AR083884A1 (es) *	2010-11-16	2013-03-27	Otsuka Pharma Co Ltd	Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) *	2010-12-14	2016-09-28	江苏豪森药业集团有限公司	一种持续释放的注射制剂及其制备方法和用途
BR112013023847B1 (pt) *	2011-03-18	2021-02-23	Alkermes Pharma Ireland Limited	composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
JO3410B1 (ar) *	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
NZ722096A (en)	2011-12-15	2016-11-25	Alkermes Pharma Ireland Ltd	Prodrugs of secondary amine compounds
CN103301461B (zh) *	2012-03-08	2018-09-07	江苏豪森药业集团有限公司	一种长效注射制剂及其制备方法和用途
AU2013235526B2 (en)	2012-03-19	2017-11-30	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) *	2012-03-19	2021-05-25	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) *	2012-03-19	2018-01-04	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising glycerol esters
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
JP6654042B2 (ja)	2012-09-19	2020-02-26	アルカームスファーマアイルランドリミテッド	貯蔵安定性が改善された医薬組成物
AR096131A1 (es)	2013-04-30	2015-12-09	Otsuka Pharma Co Ltd	Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CN106132415A (zh)	2014-03-20	2016-11-16	奥克梅斯制药爱尔兰有限公司	具有增加的注射速度的阿立哌唑制剂
CN105078898B (zh) *	2014-05-22	2018-08-28	上海现代药物制剂工程研究中心有限公司	阿立哌唑长效缓释微粒注射剂及其制备方法
ES2884849T3 (es) *	2014-08-18	2021-12-13	Alkermes Pharma Ireland Ltd	Composiciones de profármaco de aripiprazol
WO2016032950A1 (en)	2014-08-25	2016-03-03	Alkermes Pharma Ireland Limited	Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
CN106474058B (zh)	2015-08-31	2020-01-07	南京诺瑞特医药科技有限公司	具有延长的保质期的阿立哌唑可注射悬浮液制剂
EP3761983A1 (en)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
CN108498456B (zh) *	2018-05-16	2021-01-01	丽珠医药集团股份有限公司	一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) *	2019-08-06	2021-10-22	深圳市泛谷药业股份有限公司	一种阿立哌唑长效注射制剂及其制备方法
WO2021199076A1 (en)	2020-03-30	2021-10-07	Cipla Limited	Injectable aripiprazole formulation
TWI865760B (zh)	2020-04-01	2024-12-11	日商大塚製藥股份有限公司	阿立哌唑注射用製劑之投予方法
KR102378590B1 (ko) *	2020-09-28	2022-03-24	(주)위바이오트리	난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN115212174B (zh) *	2022-07-18	2024-02-20	辉粒药业(苏州)有限公司	一种载阿立哌唑长效缓释微球及其制备方法
CN115969785A (zh) *	2022-12-30	2023-04-18	辰欣药业股份有限公司	一种阿立哌唑注射剂及其制备方法
AU2024263986A1 (en)	2023-04-26	2025-10-09	Otsuka Pharmaceutical Co., Ltd.	Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5832899A (ja)	1981-08-18	1983-02-25	Takeda Chem Ind Ltd	オキセンドロン水性懸濁剤
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
FR2663223B1 (fr)	1990-06-14	1994-12-02	Af Aplicaciones Far Lab	Forme galenique parenterale.
US6294170B1 (en) *	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US7179486B1 (en) *	1997-04-01	2007-02-20	Nostrum Pharmaceuticals, Inc.	Process for preparing sustained release tablets
US6455526B1 (en) *	1998-12-16	2002-09-24	Aventis Pharmaceuticals, Inc.	Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6559128B1 (en) *	2000-01-21	2003-05-06	Northwestern University	Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US6495164B1 (en) *	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
AU2001293048A1 (en) *	2000-09-26	2002-04-08	The Johns Hopkins University	Antiviral compositions and methods of use
DE10048868A1 (de) *	2000-10-02	2002-04-11	Basf Ag	Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
JP2002191256A (ja)	2000-12-26	2002-07-09	Yoshikatsu Nakajima	水槽
CN1813699B (zh)	2001-06-14	2012-04-18	大塚制药株式会社	药物组合物
US7658998B2 (en) *	2003-01-22	2010-02-09	Alkermes Controlled Therapeutics, Inc.	Method of preparing sustained release microparticles
US6987111B2 (en) *	2003-08-06	2006-01-17	Alkermes Controlled Therapeutics, Ii	Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) *	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
ATE411797T2 (de) *	2003-10-23	2008-11-15	Otsuka Pharma Co Ltd	Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
JO3410B1 (ar) *	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
US10525057B2 (en) *	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
TWI865760B (zh) *	2020-04-01	2024-12-11	日商大塚製藥股份有限公司	阿立哌唑注射用製劑之投予方法

2003
- 2003-08-06 US US10/635,221 patent/US20050032811A1/en not_active Abandoned
2004
- 2004-07-29 EP EP10193459A patent/EP2340810A1/en not_active Withdrawn
- 2004-07-29 PL PL04779411T patent/PL1660037T3/pl unknown
- 2004-07-29 DK DK04779411.0T patent/DK1660037T3/da active
- 2004-07-29 MX MXPA06001350A patent/MXPA06001350A/es active IP Right Grant
- 2004-07-29 EP EP04779411A patent/EP1660037B1/en not_active Expired - Lifetime
- 2004-07-29 JP JP2006522614A patent/JP5300194B2/ja not_active Expired - Lifetime
- 2004-07-29 SI SI200431772T patent/SI1660037T1/sl unknown
- 2004-07-29 WO PCT/US2004/024345 patent/WO2005016262A2/en not_active Ceased
- 2004-07-29 CA CA2534997A patent/CA2534997C/en not_active Expired - Lifetime
- 2004-07-29 AU AU2004264886A patent/AU2004264886C1/en not_active Expired
- 2004-07-29 AT AT04779411T patent/ATE522200T1/de active
- 2004-07-29 PT PT04779411T patent/PT1660037E/pt unknown
- 2004-07-29 CN CN2011100063238A patent/CN102133171A/zh active Pending
- 2004-07-29 HR HR20110646T patent/HRP20110646T1/hr unknown
- 2004-07-29 ES ES04779411T patent/ES2369893T3/es not_active Expired - Lifetime
- 2004-07-29 CN CNA2004800252878A patent/CN1845721A/zh active Pending
- 2004-07-29 SE SE04779411T patent/SE1660037T5/xx unknown
- 2004-07-29 NZ NZ545037A patent/NZ545037A/en not_active IP Right Cessation
2006
- 2006-01-30 IL IL173441A patent/IL173441A/en active IP Right Grant
- 2006-02-09 NO NO20060638A patent/NO339816B1/no unknown
- 2006-02-16 ZA ZA200601385A patent/ZA200601385B/xx unknown
2008
- 2008-10-15 US US12/251,656 patent/US8338427B2/en not_active Expired - Lifetime
2010
- 2010-08-02 JP JP2010173601A patent/JP5453194B2/ja not_active Expired - Lifetime
2011
- 2011-09-29 CY CY20111100940T patent/CY1111874T1/el unknown
2012
- 2012-03-15 US US13/420,822 patent/US8338428B2/en not_active Expired - Lifetime
- 2012-10-10 US US13/648,544 patent/US8759351B2/en not_active Expired - Lifetime
2013
- 2013-10-10 JP JP2013212864A patent/JP5764634B2/ja not_active Expired - Lifetime
2014
- 2014-01-21 US US14/160,176 patent/US20140275109A1/en not_active Abandoned
2017
- 2017-08-02 US US15/666,840 patent/US20180169005A1/en not_active Abandoned
2018
- 2018-10-22 US US16/166,400 patent/US20190231679A1/en not_active Abandoned
2020
- 2020-12-21 US US17/247,708 patent/US20210346282A1/en not_active Abandoned
2023
- 2023-03-15 US US18/121,883 patent/US20230218506A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20210346282A1 (en)	2021-11-11
EP2340810A1 (en)	2011-07-06
SI1660037T1 (sl)	2012-05-31
JP5300194B2 (ja)	2013-09-25
ZA200601385B (en)	2007-02-28
US8759351B2 (en)	2014-06-24
WO2005016262A3 (en)	2005-09-09
EP1660037A2 (en)	2006-05-31
ATE522200T1 (de)	2011-09-15
CA2534997C (en)	2011-11-01
CA2534997A1 (en)	2005-02-24
MXPA06001350A (es)	2006-08-23
JP2010248258A (ja)	2010-11-04
US20180169005A1 (en)	2018-06-21
US20230218506A1 (en)	2023-07-13
US20090143403A1 (en)	2009-06-04
US8338428B2 (en)	2012-12-25
US20120289516A1 (en)	2012-11-15
JP2007501236A (ja)	2007-01-25
NO339816B1 (no)	2017-02-06
EP1660037A4 (en)	2008-09-24
IL173441A (en)	2013-04-30
WO2005016262A2 (en)	2005-02-24
US20190231679A1 (en)	2019-08-01
SE1660037T5 (pl)	2015-09-15
DK1660037T3 (da)	2011-12-12
AU2004264886A1 (en)	2005-02-24
EP1660037B1 (en)	2011-08-31
US20130090343A1 (en)	2013-04-11
US20140275109A1 (en)	2014-09-18
IL173441A0 (en)	2006-06-11
NO20060638L (no)	2006-04-26
PT1660037E (pt)	2011-10-24
JP2014001250A (ja)	2014-01-09
CY1111874T1 (el)	2015-11-04
CN102133171A (zh)	2011-07-27
HRP20110646T1 (hr)	2011-12-31
JP5453194B2 (ja)	2014-03-26
US8338427B2 (en)	2012-12-25
NZ545037A (en)	2008-10-31
ES2369893T3 (es)	2011-12-07
CN1845721A (zh)	2006-10-11
HK1091725A1 (en)	2007-01-26
US20050032811A1 (en)	2005-02-10
AU2004264886B2 (en)	2007-06-07
AU2004264886C1 (en)	2021-06-03
JP5764634B2 (ja)	2015-08-19

Publication	Publication Date	Title
SI1660037T1 (sl)	2012-05-31	Injekcijska suspenzija aripriprazoa
WO2006002365A3 (en)	2006-03-02	Microparticles with high loadings of a bioactive agent
PT1317419E (pt)	2009-05-08	Compostos e composições de ácido cianofenoxicarboxílico para administrar agentes activos
PE20050494A1 (es)	2005-08-24	Excipientes en vehiculos de suministro de farmacos
WO2007048219A3 (en)	2007-07-19	Sustained drug release composition
WO2006039704A3 (en)	2007-11-15	Pharmaceutical composition and method for treating a joint capsule arthropathy
AP2001002264A0 (en)	2001-09-30	Sustained release formulations for growth hormone secretagogues.
ATE432689T1 (de)	2009-06-15	Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
MXPA03007857A (es)	2004-05-24	Compuestos y composiciones para entregar agentes activos.
BRPI0620063B8 (pt)	2021-05-25	composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
MY151468A (en)	2014-05-30	Controlled release solid preparation
IL157955A0 (en)	2004-03-28	Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
TW200605909A (en)	2006-02-16	Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer
WO2006026592A3 (en)	2006-09-14	Oral administration of poorly absorbed drugs, methods and compositions related thereto
SI1596841T1 (sl)	2009-06-30	Terapevtski sistem amoksicilina in klavulanske kisline
UA86528C2 (uk)	2009-04-27	Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону
WO2005030132A3 (en)	2006-10-12	Therapeutic regimens for administering drug combinations
IL179177A (en)	2013-05-30	A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
EP1634585A4 (en)	2009-08-12	MEDICINAL PRODUCTS CONTAINING DELAYED MICROTEIL, PROCESS FOR ITS PREPARATION AND MICROPARTICLE CONTAINING PREPARATION
WO2004033484A3 (en)	2004-06-10	Use of stable glutamine derivatives to improve drug absorption
ATE334658T1 (de)	2006-08-15	Arzneimittel zur verabreichung an schleimhäute
MY153696A (en)	2015-03-13	Solid pharmaceutical formulation
WO2005062874A3 (en)	2005-12-15	Compounds and compositions for delivering active agents
BR0315231A (pt)	2005-08-23	Compostos com base em glicose com afinidade para p-seletina
ATE429905T1 (de)	2009-05-15	Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung